<DOC>
	<DOCNO>NCT02204904</DOCNO>
	<brief_summary>Study ALD 103 multi-site , global , data collection study design evaluate safety efficacy allogenic hematopoietic stem cell transplantation ( allo-HSCT ) patient CALD age 17 younger .</brief_summary>
	<brief_title>Observational Study Evaluate Allogeneic HSCT Outcomes Cerebral Adrenoleukodystrophy ( CALD )</brief_title>
	<detailed_description>Study ALD-103 multi-site , global , prospective retrospective data collection study design evaluate outcome allo-HSCT male subject ≤17 year age CALD . Retrospective subject ≤17 year age time treatment ; prospective subject ≤17 year age time consent . This observational study involve use investigational drug medicinal product . It allow collection specific data point related allo-HSCT procedure outcome . Suitability allo-HSCT choice treatment protocol utilized subject determine subject ' treat physician per institutional policies/protocols local treatment guideline . Procedures perform accord institutional protocol accept management CALD , include supportive care , choice graft source , allo-HSCT protocol , prophylaxis , management graft-versus-host disease ( GVHD ) . Subjects monitor Screening allo-HSC infusion , Month 48 Visit allo-HSC infusion . Follow-up include monitor outcome measure Months 1 , 2 , 3 , 6 , 9 , 12 , 18 , 24 , 36 , 48 allo-HSC infusion ( prospective analysis ) . In addition subject prospective analysis , subject receive allo-HSCT January 1 , 2013 available least Month 24 visit ( 24 ± 1 month allo-HSC infusion ) may also enrol follow Month 48 Visit recent allo-HSC infusion ( partial prospective analysis retrospective analysis , applicable ) .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>1 . Provide informed consent competent custodial parent guardian legal capacity execute local Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve consent . In addition , inform assent seek capable subject , accordance directive institution 's IRB/IEC local requirement . 2 . Be male age 17 year young ( i.e. , &lt; 18 year age ) time parental/guardian consent , appropriate , subject assent . 3 . Have confirm diagnosis CALD define abnormal VLCFA profile cerebral lesion brain MRI . 4 . Be schedule alloHSCT evaluation/procedure ( prospective ) study site receive recent alloHSC infusion January 1 , 2013 . 1 . Previous treatment gene therapy product . 2 . Received recent alloHSC infusion prior January 1 , 2013 .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>X-linked Adrenoleukodystrophy</keyword>
	<keyword>Hematopoietic Stem Cells</keyword>
</DOC>